Studies have shown that the selective inhibition of CDK1, PBK, and CHEK1 arrests tumor progression in sarcomas, GBM, prostate, endometrial, and breast cancers by blocking the G2-M phase transition and promoting apoptosis [1,9,35,36,37,38,39,40,41]. Here, PBK is linked to neoplasm.